|
⚲
|
| Keyboard |
| RP Management LLC
✚
|
|
|---|---|
| CRD # | 161569 |
| SEC # | 801-74235 |
| CIK # | 0001507673 |
| AUM | 2,139.0 M (2026-03-31) |
| Employees | 2 (50% Investors, 0% Brokers) |
| Phone | 212-883-0200 |
| Address | 110 East 59th Street, Suite 3300 New York, NY 10022 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Royalty Pharma Select | [2021-04-29] | 164.5 M | 40.9 M |
| Filed 2017-04-10 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | RPI Intermediate Finance Partnership LP | [2021-04-29] | 0.5 M | 1,194.2 M |
| Filed 2011-08-24 (D) · Exemption 506, 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | RPI International Holdings 2019 LP | [2020-03-27] | 1,046.3 M | |
| Filed 2020-02-10 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| PE | RPS Biopharma Holdings LP | [2020-03-27] | 149.6 M | 32.8 M |
| Filed 2017-04-10 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| PE | RPS Biopharma Holdings LP | 2018-03-29 | 72.8 M | |
| PE | RPS Biopharma Investments LP | [2018-03-29] | 164.5 M | 29.6 M |
| Filed 2017-04-10 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| PE | Royalty Pharma Cayman Holdings 2008 LP | [2012-02-15] | 0.7 M | |
| PE | Royalty Pharma Cayman Holdings LP | 2012-02-15 | 61.9 M | |
| PE | Royalty Pharma Cayman Partners 2008 LP | 2012-02-15 | 0.7 M | |
| PE | Royalty Pharma Cayman Partners LP | [2012-02-15] | 61.9 M | |
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 7 | 2.1 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 7 | 2.1 |
| By Discretionary | ||
| Discretionary | 7 | 2.1 |
| Non-Discretionary | 0 | 0.0 |
| Total | 7 | 2.1 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 2.1 | |
| Total | 7 | 2.1 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Rory Riggs | Director | 36 | 3 | |
| Pablo Legorreta | Director, Executive Officer | 12 | 3 | |
| Pharma Management Cayman Ltd | Promoter | 3 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001507673] | |
| 3 | [0001507673] | |
| 4 | [0001507673] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $8.6B |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| RPI Finance Trust | |
| Royalty Pharma Investments 2019 ICAV | |
| Legorreta Pablo G | |
| Epizyme Inc | |
| RP Management LLC |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Epizyme Inc EPZM
Common Stock, par value $0.0001
|
2022-08-12 | Tender | 31,933,334 | ||
|
Epizyme Inc EPZM
Restricted Stock Units · derivative
|
2022-08-12 | Disposed to issuer | 8,994 | $0.00 | |
|
Epizyme Inc EPZM
Restricted Stock Units · derivative
|
2022-08-12 | Disposed to issuer | 8,060 | $0.00 | |
|
Epizyme Inc EPZM
Restricted Stock Units · derivative
|
2022-05-17 | Grant | 8,994 | $0.00 | |
|
Epizyme Inc EPZM
Stock Option (Right to Buy) · derivative
|
2022-05-17 | Grant | 41,006 | $0.56 | 22,963 |
|
Epizyme Inc EPZM
Common Stock
|
2022-01-31 | Buy | 22,666,667 | $1.50 | 34,000,000 |
|
Epizyme Inc EPZM
Stock Option (Right to Buy) · derivative
|
2021-06-11 | Grant | 40,559 | $8.53 | 345,968 |
|
Epizyme Inc EPZM
Restricted Stock Units · derivative
|
2021-06-11 | Grant | 8,060 | $0.00 | |
|
Epizyme Inc EPZM
Stock Option (Right to Buy) · derivative
|
2020-05-29 | Grant | 14,103 | $0.00 | |
|
Epizyme Inc EPZM
Common Stock
|
2020-02-11 | Grant | 2,500,000 | $20.00 | 50,000,000 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Teng Yue Partners LP
✚
|
NY | 2,247.5 M |
|
Mason Capital Management LLC
✚
|
NY | 2,237.5 M |
|
FEG Investment Services LLC
✚
|
OH | 2,230.7 M |
|
LUPA RIA Investment Management LLC
✚
|
NY | 2,189.3 M |
|
Catalio Capital Management LP
✚
|
NY | 2,176.6 M |
|
Albion River Management LLC
✚
|
MD | 2,062.2 M |
|
Flat Footed LLC
✚
|
WY | 2,059.5 M |
|
Pleasant Lake Partners LLC
✚
|
PR | 2,055.9 M |
|
Blue Road Management LP
✚
|
NY | 2,043.6 M |
|
Advent Global Opportunities Management LLC
✚
|
MA | 2,015.8 M |